Markedly elevated soluble E cadherin in plasma of patient with pelvic inflammatory disease
The level of plasma soluble E-cadherin was elevated in patients with pelvic inflammatory disease as compared with that in normal controls and in the same patients after they received treatment.
Hsiu-Ting Tsai, Ph.D., Tsung-Hsien Lee, M.D., Ph.D., Shun-Fa Yang, Ph.D., Long-Yau Lin, M.D., Sc.D., Yi-Torng Tee, M.D., Ph.D., Po-Hui Wang, M.D., Ph.D.
Volume 99, Issue 2, Pages 490-495, February 2013
To estimate the expression of plasma soluble E-cadherin and the gene polymorphism in patients with pelvic inflammatory disease (PID).
Hospital-based case-control study.
Sixty-four women with PID.
Blood specimen collection of patients before and after they received treatment.
Main Outcome Measure(s):
Enzyme-linked immunosorbent assay and polymerase chain reaction–restriction fragment length polymorphism were respectively used to measure the plasma soluble E-cadherin level and E-cadherin polymorphism.
The level of plasma E-cadherin was significantly elevated in PID patients as compared to that in normal controls; it decreased significantly after treatment when compared to levels noted in same patients after they received treatment. When the cutoff level of plasma E-cadherin level was set to be 20.22 ng/ml based on ROC, the sensitivity, specificity, and the area under the curve of plasma E-cadherin level for predicting PID were 0.81, 0.80, and 0.835 (95% confidence interval (CI), 0.76-0.90). The adjusted odds ratio (AOR) for age, WBC, and CRP levels is 19.66 (5.48-70.47).
Elevated plasma soluble E-cadherin expression was involved in the pathogenesis of PID and useful for the diagnosis of PID.